Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VERA Stock Forecast 2026-2027
$48.41
Current Price
$3.44B
Market Cap
Buy 12
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to VERA Price Targets
+106.6%
To High Target of $100.00
+50.8%
To Median Target of $73.00
-31.8%
To Low Target of $33.00
VERA Price Momentum
+1.5%
1 Week Change
-1.6%
1 Month Change
+42.9%
1 Year Change
-4.4%
Year-to-Date Change
-13.6%
From 52W High of $56.05
+161.3%
From 52W Low of $18.53
📊 TOP ANALYST CALLS
Did VERA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vera Therapeutics is one of their latest high-conviction picks.
Latest VERA Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, VERA has a bullish consensus with a median price target of $73.00 (ranging from $33.00 to $100.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $48.41, the median forecast implies a 50.8% upside. This outlook is supported by 12 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Pete Stavropoulos at Cantor Fitzgerald, projecting a 106.6% upside. Conversely, the most conservative target is provided by Laura Chico at Wedbush, suggesting a 31.8% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VERA Analyst Ratings
12
Buy
2
Hold
0
Sell
VERA Price Target Range
Low
$33.00
Average
$73.00
High
$100.00
Current: $48.41
Latest VERA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VERA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 19, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $96.00 |
| Dec 19, 2025 | B of A Securities | Dina Ramadane | Buy | Maintains | $66.00 |
| Dec 19, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $95.00 |
| Dec 11, 2025 | Wedbush | Laura Chico | Neutral | Maintains | $33.00 |
| Dec 8, 2025 | Evercore ISI Group | Gavin Clark-Gartner | Outperform | Maintains | $97.00 |
| Dec 5, 2025 | TD Cowen | Ritu Baral | Buy | Maintains | $73.00 |
| Nov 10, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $90.00 |
| Nov 7, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $52.00 |
| Oct 16, 2025 | B of A Securities | Dina Ramadane | Buy | Initiates | $48.00 |
| Aug 7, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $53.00 |
| Aug 4, 2025 | Wolfe Research | Andy Chen | Peer Perform | Downgrade | $N/A |
| Jun 2, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $85.00 |
| Jun 2, 2025 | Scotiabank | Greg Harrison | Sector Outperform | Maintains | $65.00 |
| May 12, 2025 | Scotiabank | Sector Outperform | Maintains | $N/A | |
| May 7, 2025 | Wedbush | Laura Chico | Neutral | Maintains | $26.00 |
| May 7, 2025 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Maintains | $100.00 |
| May 5, 2025 | HC Wainwright & Co. | Arthur He | Buy | Assumes | $75.00 |
| Mar 4, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $71.00 |
| Feb 27, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $61.00 |
| Feb 4, 2025 | Wolfe Research | Andy Chen | Outperform | Initiates | $49.00 |
Vera Therapeutics Inc. (VERA) Competitors
The following stocks are similar to Vera Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VERA
Vera Therapeutics
mkt cap
3.46B
Vera Therapeutics Inc. (VERA) Financial Data
Vera Therapeutics Inc. has a market capitalization of $3.44B with a P/E ratio of -17.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -73.2%.
Valuation Metrics
Market Cap
$3.44B
Enterprise Value
$2.72B
P/E Ratio
-17.3x
PEG Ratio
-0.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.1%
Current Ratio
12.2x
Debt/Equity
19.4x
ROE
-73.2%
ROA
-38.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vera Therapeutics Inc. (VERA) Business Model
About Vera Therapeutics Inc.
What They Do
Biotechnology company developing therapies for immune diseases.
Business Model
Vera Therapeutics focuses on researching and developing innovative therapies to treat immune-mediated diseases, primarily through its lead asset, atacicept. The company aims to generate revenue by advancing its products through clinical trials and obtaining regulatory approval, ultimately leading to commercialization and sales in markets with significant unmet medical needs.
Additional Information
The company emphasizes addressing conditions like immunoglobulin A nephropathy (IgAN) and is positioned in a rapidly evolving biotech sector. Vera Therapeutics is dedicated to improving patient outcomes and expanding treatment options in areas that have been inadequately served by existing pharmaceutical solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
224
CEO
Dr. Marshall W. Fordyce M.D.
Country
United States
IPO Year
2021
Website
veratx.comVera Therapeutics Inc. (VERA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High?
The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Jan 14, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Vera Therapeutics granted inducement awards of 228,750 stock options and 116,000 RSUs to 18 new employees under its 2024 Inducement Plan on January 5, 2026.
Why It Matters
The grant of stock options and RSUs to new employees indicates company growth and potential expansion, which can enhance investor confidence and impact stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A biotech company has submitted a biologics license application for its kidney disease drug, which has been accepted for priority review by the FDA.
Why It Matters
The acceptance of the biologics license application for priority review signals potential accelerated approval and market entry, which could significantly impact the biotech's stock value and revenue prospects.
Source: The Motley Fool
Market Sentiment:
Positive
FDA Fast-Tracks Vera's At-Home Kidney Drug
8 days ago
Quick Summary
Vera Therapeutics' stock rose after the FDA accepted its atacicept Biologics License Application for Priority Review.
Why It Matters
The FDA's acceptance of Vera Therapeutics' atacicept BLA for Priority Review signals potential accelerated approval, likely boosting investor confidence and stock value.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Vera Therapeutics received U.S. FDA Priority Review for its Biologics License Application for Atacicept, aimed at treating adults with IgA Nephropathy.
Why It Matters
The FDA's priority review for Atacicept could accelerate its market entry, potentially increasing Vera Therapeutics' revenue and stock value if approved.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Wells Fargo analysts suggest that tax refund spending, improved earnings, and Federal Reserve liquidity could drive a rebound in equities, especially for heavily shorted stocks in the Russell 3000.
Why It Matters
Potential tax refund spending and Fed liquidity could boost equities, especially heavily shorted stocks in the Russell 3000, signaling a possible market rebound.
Source: Invezz
Market Sentiment:
Positive
Quick Summary
Vera Therapeutics priced an underwritten public offering of 6,138,108 shares of Class A common stock at $42.50 per share, focused on treatments for serious immunologic diseases.
Why It Matters
Vera Therapeutics' public offering at $42.50 per share raises capital, impacting liquidity and future growth potential, which can influence stock valuation and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VERA Stock
What is Vera Therapeutics Inc.'s (VERA) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Vera Therapeutics Inc. (VERA) has a median price target of $73.00. The highest price target is $100.00 and the lowest is $33.00.
Is VERA stock a good investment in 2026?
According to current analyst ratings, VERA has 12 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $48.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VERA stock?
Wall Street analysts predict VERA stock could reach $73.00 in the next 12 months. This represents a 50.8% increase from the current price of $48.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vera Therapeutics Inc.'s business model?
Vera Therapeutics focuses on researching and developing innovative therapies to treat immune-mediated diseases, primarily through its lead asset, atacicept. The company aims to generate revenue by advancing its products through clinical trials and obtaining regulatory approval, ultimately leading to commercialization and sales in markets with significant unmet medical needs.
What is the highest forecasted price for VERA Vera Therapeutics Inc.?
The highest price target for VERA is $100.00 from Pete Stavropoulos at Cantor Fitzgerald, which represents a 106.6% increase from the current price of $48.41.
What is the lowest forecasted price for VERA Vera Therapeutics Inc.?
The lowest price target for VERA is $33.00 from Laura Chico at Wedbush, which represents a -31.8% decrease from the current price of $48.41.
What is the overall VERA consensus from analysts for Vera Therapeutics Inc.?
The overall analyst consensus for VERA is bullish. Out of 18 Wall Street analysts, 12 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $73.00.
How accurate are VERA stock price projections?
Stock price projections, including those for Vera Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 15, 2026 6:32 PM UTC